Mucuna pruriens proves more effective than L-DOPA in Parkinson's disease animal model

Phytotherapy Research

Volumn 11, Issue 6, 1997, Pages 419-423

  Hussain, Ghazala ^a   Manyam, Bala V ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxy dopamine; Ayurveda; L DOPA; Mucuna pruriens; Parkinson's disease; Rat

Indexed keywords

AMPHETAMINE; AYURVEDIC DRUG; CARBIDOPA; LEVODOPA; MUCUNA PRURIENS EXTRACT; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; RAT;

MUCUNA PRURIENS;

EID: 0030844903     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1573(199709)11:6<419::AID-PTR120>3.0.CO;2-Q     Document Type: Article

References (30)

1. Bell, E. A., and Janzen, D. H. (1971). Medical and ecological considerations of L-dopa and 5-HTP in seeds. Nature 229, 136-137.
2. Budavari, S. ed. (1989). The Merck Index, 11th edn, pp. 860, Merck Res. Labs., Rathway, NJ.
3. Chase, T. N. (1972). Drug-induced extrapyramidal disorders. In Proceedings of the Association for Research in Nervous and Mental Disorders, pp. 448-466. Williams & Wilkins, Baltimore.
4. Damodaran, M., and Ramaswamy, R. (1937). Isolation of L-dopa from the seeds of Mucuna pruriens. Biochemistry 31, 2149-2151.
5. Daxenbichler, M. E., VanEtten, C. H., Hallinan, E. A. and Earle, F. R. (1971). Seeds as sources of L-dopa. J. Med. Chem. 41, 463-465.
6. Dutt, V. C. (1980). Materia Medica of the Hindus (Krishnades Sanskrit Studies Vol II), pp. 148-149. Chowhamba Saraswalibhawan, Varanasi.
7. Fuxe, K., and Ungerstedt, U. (1970). Histochemical, biochemical and functional studies on central monoamine neurons after acute and chronic amphetamine administration. In, Amphetamines and Related Compounds, ed. by E. Costa and S. Garattini, pp. 257-288. Raven, New York.
8. Harris, R. B., Hughes, L. F., Elble, R. J. and Manyam, B. V. (1991). Parkinson's disease: factors of importance in rehabilitation. Tenth International Symposium on Parkinson's disease. Tokyo, Japan, 27-30 October.
9. Hornykiewicz, O. (1964). Zur Frage des Verlaug's domaminerger Neurone im Gehirn des Menschen. Wien. Klin. Wschr. 767, 834-835.
10. HP-200 in Parkinson's Disease Study Group (Manyam, B. V., Senior Author). (1995). HP-200: An 'Alternative Medicine' Treatment for Parkinson's disease. J. Alternat. Comp. Med. 1, 249-255.
11. Kaakkola, S., and Teravainen, H. (1990). Animal models of Parkinsonism. Pharmacol. Toxicol. 67, 95-100.
12. Lattanzio, V., Bianco, V. V. and Lafiandra, D. (1982). High-performance reversed-phase liquid chromatography (HPLC) of favism-inducing factors in Vicia faba L. Experientia 38, 789-790.
13. Mahajani, S. S., Doshi, V. J., Parikh, K. M., and Manyam, B. V. (1996). Bioavailability of L-dopa from HP-200 - a formulation of seed powder of Mucuna pruriens. A pharmacokinetic and pharmacodynamic study. Phytother. Res. 10, 254-256.
14. Manyam, B. V. (1990). Paralysis agitans and levodopa in "Ayurveda," ancient Indian medical treatise. Mov. Disord. 5, 47-48.
15. Nadkarni, K. M. (1908). Indian Plants and Drugs, p. 242. Norton & Co., Madras.
16. Norman, T. R., Chamberlain, K. G., French, M. A., and Burrows, G. D. (1982). Platelet monoamine oxidase activity and cigarette smoking. J. Affect. Dis. 4, 73-77.
17. Parkes, D. (1977). Bromocriptine. Adv. Drug Res. 12, 248-331.
18. Paxinos, G., and Watson, C. (1986). The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press Ltd., London.
19. Perese, D. A., Ulman, J., Viola, J., Ewing, S. E., and Bankiewicz, K. S. (1989). A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 494, 285-293.
20. Sanchez-Ramos, J. R. (1991). Banisterine and Parkinson's disease. Clin. Neuropharmacol. 14, 391-402.
21. Schultz, W., and Ungerstedt, U. (1978). Straital cell supersensitivity to apomorphine in dopamine-lesioned rats correlated to behaviour. Neuropharmacol. 17, 349-353.
22. Singhal, G. D., Singh, R. H., and Shukla, K. P. (1979). Non-operative considerations in ancient Indian surgery (based on Susruta Samhita, Cikitsa-Sthana, chapters 24-40). Singhal Publications, Varanasi.
23. Ungerstedt, U., and Arbuthnott, G. W. (1970). Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493.
24. Ungerstedt, U., Avema, A. D., Ljundberg, T., and Runge, C. (1973). Animal models of Parkinsonism. Adv. Neurol. 3, 257-271.
25. Vaidya, A. B., Rajogopalan, T. G., Mankodi, N. A. et al. (1978). Treatment of Parkinson's disease with the Cowhage plant - Mucuna pruriens bark. Neurology India 26, 171-176.
26. Vaidya, N. D. (1925). A Treatise on Experienced Remedies, p. 100. Vaidya-Kalapataru, Ahmeabad.
27. Vaidya, R. A., Sheth, A. R., Aloorkar, S. D. et al. (1978). The inhibitory effect of the Cowhage plant - Mucuna pruriens - and L-Dopa on chlorpromazine-induced hyperprolactinaemia in man. Neurology India 26, 177-182.
28. Walsh, M. J. and Silbergeld, E. K. (1979). Rat rotation monitoring for pharmacology research. Pharma. Biochem. Behav. 10, 433-436.
29. Wardell, W. M., and Shek, L. E. (1983). Is pharmaceutical innovation declining? Interpreting measures of pharmaceutical innovation and regulatory impact in the USA 1950-1980. Rational Drug Ther. 17, 1.
30. Zetterstrom, T., Herrara-Marschitz, M., and Ungerstedt, U. (1986). Simultaneous measurement of dopamine release and rotational behavior in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 376, 1-7.